Fulvestrant for Adenocarcinoma
This study is evaluating whether a combination of two drugs may help treat breast cancer.
See full descriptionAbout the trial for Adenocarcinoma
Treatment Groups
This trial involves 2 different treatments. Fulvestrant is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
About The Treatment
Eligibility
This trial is for female patients aged 18 and older. You must have received 1 prior treatment for Adenocarcinoma or one of the other 2 conditions listed above. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Fulvestrant will improve 1 primary outcome in patients with Adenocarcinoma. Measurement will happen over the course of 1 year.
Patient Q & A Section
How many people get adenocarcinoma a year in the United States?
About 5.5 million cases of colorectal adenocarcinoma are diagnosed in the United States each year, making it one of the most frequently diagnosed malignancies in the country.
Can adenocarcinoma be cured?
A curative operation has not been achieved with advanced carcinoma of the rectum. However more cases need to be presented with this tumor type to make a valid statement.
What is adenocarcinoma?
Adenocarcinoma is the most common histologic subtype of carcinoma of the esophageal epithelium and the fifth most common type of esophageal carcinoma, with an overall 5-year survival rate of less than 20%. Adenocarcinomas of the esophagogastric junction are less aggressive than gastroesophageal adenocarcinoma and have a good prognosis and are more curable than distal esophageal adenocarcinoma. It is imperative that all carcinomas of the esophagus be reported and diagnosed optimally so that better long-term outcomes can be achieved.
What are the signs of adenocarcinoma?
Adenocarcinoma presents with painful or abnormal weight loss, or lump or mass on the skin. Abnormalities on blood tests include anemia and low or high white blood cells.\n\nNumerous medications are being developed to treat cancer. Some are specifically developed by chemists in order to target certain types of cancer. For example, paclitaxel, a naturally occurring chemical that causes uncontrolled cell death through the use of mitochondrial swelling, can affect many tumors. Others are drugs that are used to treat cancer, but also induce a change in the rate of normal cell growth. The two main groups of this kind include anthracyclines and antimetabolites.
What are common treatments for adenocarcinoma?
A significant challenge in cancer treatment is to identify effective therapies for particular individuals, particularly for stage IV cancer. In stage IV cancer, the survival rates are worse in women than in men. Women with stage IV disease who undergo chemotherapy had an improved survival rate than women who were not treated (21% vs 11% at 3 years, P = 0.014). Women who received chemotherapy reported significantly greater improvements in symptoms ( P = 0.007), physical functioning ( P = 0.004), and mental functioning ( P = 0.018) than women who did not undergo chemotherapy. Women also displayed a significantly greater decline in symptoms ( P = 0.018), physical functioning ( P = 0.028), and mental functioning ( P = 0.
Who should consider clinical trials for adenocarcinoma?
Patients who did not wish to receive any therapy were most likely to be eligible for clinical trials. Clinical trials for adenocarcinoma are a worthwhile investment and should be offered to patients and their families.
Is fulvestrant safe for people?
Fulvestrant may be safely administered to people over 75 years of age, but its use may be limited for people in older age groups. The risk of serious and fatal thromboembolism is very low (the risk is about 0.9%). The incidence of peripheral edema is lower than that reported in clinical trials.
What is fulvestrant?
The therapeutic efficacy of fulvestrant is related to its potentiation of the growth-inhibitory activity of ERβ in breast cancer cell lines. It does not act via other functions of the ER such as ERα/β ligand binding, and therefore may be considered a preferential ERβ agonist.
What is the average age someone gets adenocarcinoma?
Adenocarcinoma is the second most common cause of death from breast cancer; the average person is 47. If you had a [complete course of treatment for breast cancer], you might have a few years to live and to have one last big vacation.\n
Have there been any new discoveries for treating adenocarcinoma?
After almost a decade of research, the understanding of the progression of adenocarcinoma and how we can prevent it remain unsatisfying. As with many cancers, adenocarcinoma can be managed using many different treatment strategies; however, our goal remains to find therapies that selectively target adenocarcinoma without harming the surrounding normal tissue. To date, such therapies have been found using novel targeted therapies, and newer treatment strategies are also in the final stages of testing. However, because adenocarcinoma is an aggressive cancer and carries a poor prognosis, the use of targeted therapies is critical to improving outcomes for people who have it.
Does fulvestrant improve quality of life for those with adenocarcinoma?
Fulvestrant reduced pain, improved the degree of HRQOL and Q-LQPAD. There was high consistency in patient-reported HRQOL assessments. These data indicate that patients with HRQoL parameters in the low end of the spectrum may benefit from this agent. HRQoL assessment using the FACT can provide clinicians and patients with useful information about efficacy, which can be critical to the decision-making process.